ethyl N-(4-methoxybenzyl)oxamate | 77245-39-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl N-(4-methoxybenzyl)oxamate
• 英文别名: ethyl 2-((4-methoxybenzyl)amino)-2-oxoacetate；ethyl 2-[(4-methoxyphenyl)methylamino]-2-oxoacetate
• CAS: 77245-39-7
• 化学式: C₁₂H₁₅NO₄
• 分子量: 237.255
• InChiKey: ITKVMJWKVNKTPE-UHFFFAOYSA-N

物化性质

• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl N-(4-methoxybenzyl)oxamate 在 吡啶 、 氢氧化钾 、 迭氮酸 、 五氯化磷 作用下， 以 乙醇 、 二氯甲烷 、 苯 为溶剂， 反应 7.0h， 生成 potassium 1-(4-methoxybenzyl)tetrazole-5-carboxylate
  参考文献：
  名称：

  5-四唑甲酰胺及其盐：新型口服活性抗过敏药。

  摘要：

  DOI：

  10.1021/jm00138a021
• 作为产物：
  描述：

  草酰氯单乙酯 、 4-甲氧基苄胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 以96%的产率得到ethyl N-(4-methoxybenzyl)oxamate
  参考文献：
  名称：

  [EN] TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS
  [FR] TRIAZOLOPYRAZINONES UTILISÉES COMME INHIBITEURS DE PDE1

  摘要：

  本发明提供三唑吡嗪酮作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。

  公开号：

  WO2016055618A1

文献信息

• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20090011994A1

  公开（公告）日：2009-01-08

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。
• SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20110144060A1

  公开（公告）日：2011-06-16

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了一种化合物，包括所有立体异构体、溶剂化合物、前药和其制备的药学上可接受的形式，其化学式为I式，其中R1、R2、R3、R8和R9的定义如本文所述。此外，本申请还提供了含有至少一种I式化合物和可选的至少一种其他治疗剂的药物组合物。最后，本申请提供了通过给予I式化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或疾病的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症。
• Modular Synthesis of Polar Spirocyclic Scaffolds Enabled by Radical Chemistry
  作者：Khadijah Anwar、Francisco José Aguilar Troyano、Ayham H. Abazid、Oumayma El Yarroudi、Ignacio Funes-Ardoiz、Adrián Gómez-Suárez

  DOI：10.1021/acs.orglett.3c00869

  日期：2023.5.12

  Herein, we report a highly modular strategy to access spirocyclic scaffolds from abundant starting materials, i.e., cyclic ketones and α-amino or oxamic acids. The sequence proceeds through a straightforward Knoevenagel condensation, followed by a domino Giese-type reaction/base-mediated cyclization process, to deliver a broad scope of polar spirocyclic scaffolds in good to excellent yields. The products

  在此，我们报告了一种高度模块化的策略，可以从丰富的起始材料（即环酮和 α-氨基或草酸）中获取螺环支架。该序列通过直接的 Knoevenagel 缩合进行，然后是多米诺 Giese 型反应/碱基介导的环化过程，以良好到极好的收率提供范围广泛的极性螺环支架。产品可以很容易地多样化，从而增加我们方法的通用性，以快速访问潜在的类药物分子库。
• Triazolopyrazinones as PDE1 inhibitors
  申请人：H. Lundbeck A/S

  公开号：US10150771B2

  公开（公告）日：2018-12-11

  The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了作为 PDE1 抑制剂的三唑吡嗪酮及其作为药物的用途，特别是用于治疗神经退行性疾病和精神疾病。
• Practical Synthesis of Functionalized 1,5-Disubstituted 1,2,4-Triazole Derivatives
  作者：Yingju Xu、Mark McLaughlin、Emily N. Bolton、Robert A. Reamer

  DOI：10.1021/jo1017603

  日期：2010.12.17

  A general approach for the synthesis of 1,5-disubstituted-1,2,4-triazole compounds is described. A series of new oxamide-derived amidine reagents can be accessed in excellent yield with minimal purification necessary. Typically, these amidine reagents are stable crystalline solids and in certain cases were found to exist in a cyclic form as determined by NMR spectroscopy. Under optimized conditions, the direct reaction of these prepared reagents with various hydrazine hydrochloride salts efficiently generates the target triazoles. Both aromatic and aliphatic hydrazines react readily with the amidine reagents under very mild reaction conditions, delivering desired 1,5-disubstituted-1,2,4-triazole derivatives in good yields.